Inclusion Criteria:

- Informed consent form signed before performing any of the study's specific
procedures.

- ECOG performance status 0-2.

- Age > 18，both genders.

- Metastatic colorectal cancer confirmed by pathology, or locally advanced unresectable
colorectal cancer, or postoperative recurrence and metastasis colorectal cancer

- Disease progression after receiving oxaliplatin ± fluorouracil in first-line
treatment

- At least 1 measurable lesions ,( longest diameter≥ 1 cm by spiral computed tomography
(CT) scan or MRI)

- Life expectancy more than 3 months.

- K-ras is wild type

- Use of an effective contraceptive method for patients of both sexes when there is a
risk of conception and/or pregnancy.

- Liver metastasis, lesions smaller than 50% of the liver; Lung metastasis, lesions
smaller than 30% of the lung

- Haemoglobin≥90g/L , granulocyte≥1.5×109/L ,WBC ≥3×109/L, platelet count≥100×109/L

- TBIL≤ 1.5 x ULN ,ALK≤ 2.5 x ULN or ≤ 5ULN（Liver metastasis），AST and ALT≤ 2.5 x ULN or
≤ 5ULN（Liver metastasis）,Creatinine ≤ 1.5 x ULN

- No brain metastasis

Exclusion Criteria:

- Previous radiotherapy at lesions within three months

- Other first line chemo-agents treatment except oxaliplatin ± fluorouracil

- Received other anti EGFR monoclonal antibody treatment

- Complete or incomplete intestinal obstruction

- Participation in other interventional clinical trials within 1 month

- Psychiatric disease affected cognitive ability, including brain metastasis

- Peripheral neuropathy lesion is more than I stage

- History of serious allergic or allergy

- Pregnant or breast-feeding women

- Patients with the history of Serious lung or hear disease

- Other malignant tumor